Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cefepime Hydrochloride

FDA-approved product (injectable, injection), marketed as Cefepime And Dextrose In Duplex Container, Cefepime Hydrochloride, Cefepime Hydrochloride In Plastic Container and 2 more.

Registered studies
50+
Lab records
203
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cefepime Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacteriemia
  • Infection
  • Pneumonia
  • Pyelonephritis
  • Sprain
  • Urinary tract infection
  • Ventilator-associated pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fourth-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DE01

Repurposing investigation

Cefepime Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli98.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis50.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 95 of 203 lab records
Open Cefepime Hydrochloride in ChEMBL Registered studies below
Show the latest 150 of 203 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefepime Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacodynamic Parameters of Two Different Doses of Cefepime

    NCT00177736 · start 2005-09

    Registered record
    Registry ID
    NCT00177736
    Conditions
    Infection; Bacteremia; Pneumonia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-09
    Completion
    2007-12
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection; Bacteremia; Pneumonia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia

    NCT00358202 · start 2002-03

    Registered record
    Registry ID
    NCT00358202
    Conditions
    Pneumonia
    Interventions
    cefepime; ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-03
    Completion
    2006-04
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    Interventioncefepime; ceftriaxone
    PhasePhase 4
    Registry statusCompleted

  • Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia

    NCT00020865 · start 2001-09

    Registered record
    Registry ID
    NCT00020865
    Conditions
    Fever, Sweats, and Hot Flashes; Infection; Leukemia; Lymphoma; Neutropenia; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    cefepime hydrochloride; levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2001-09
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFever, Sweats, and Hot Flashes; Infection; Leukemia; Lymphoma +2 more
    Interventioncefepime hydrochloride; levofloxacin
    PhasePhase 3
    Registry statusUnknown

  • Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

    NCT00044759

    Registered record
    Registry ID
    NCT00044759
    Conditions
    Hematologic Neoplasms
    Interventions
    Piperacillin/Tazobactam (Tazocin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2003-01
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematologic Neoplasms
    InterventionPiperacillin/Tazobactam (Tazocin)
    PhasePhase 3
    Registry statusCompleted

  • Direct E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia

    NCT01042353

    Registered record
    Registry ID
    NCT01042353
    Conditions
    Ventilator Acquired Pneumonia
    Interventions
    E test; standard culture method
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Acquired Pneumonia
    InterventionE test; standard culture method
    PhasePhase 4
    Registry statusCompleted